Azenta, Inc. (AZTA) - Form 10-Q Summary
Business Context and Reporting Period
Company: Azenta, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Azenta is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. Operations are organized into two reportable segments: Sample Management Solutions (SMS) and Multiomics. The company recently completed the sale of its B Medical Systems business, which is now classified as a discontinued operation.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Nine Months Ended June 30, 2026 |
Nine Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $161,178 | $454,615 | $434,629 |
| Gross Profit | $72,356 | $198,097 | $198,006 |
| Gross Margin | 45.0% | 43.6% | 45.6% |
| Operating Loss | $(4,178) | $(177,205) | $(28,745) |
| Net Income (Loss) | $2,456 | $(173,774) | $(106,640) |
| Diluted EPS | $0.05 | $(3.80) | $(2.33) |
| Cash & Equivalents | $189,654 | Balance Sheet as of June 30, 2026 | |
| Marketable Securities | $332,230 | Balance Sheet as of June 30, 2026 | |
| Total Debt | $0 | No outstanding debt |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 12% year-over-year for the quarter and 5% for the nine-month period. Growth was driven by the SMS segment (Sample Storage, Consumables, and UK Biocentre acquisition) and the Multiomics segment (Next Generation Sequencing and Gene Synthesis).
- Goodwill Impairment: A significant non-cash goodwill impairment charge of $149.1 million was recorded in the first quarter of fiscal 2026 (included in the nine-month results). This charge comprised $112.4 million for the Multiomics segment and $36.6 million for the SMS segment, driven by declining stock prices and revised forecasts.
- Discontinued Operations: The B Medical Systems business was sold on July 1, 2026, for $63.0 million. Results for this business are reported as discontinued operations, contributing a net income of $4.0 million for the quarter and a net loss of $10.0 million for the nine months ended June 30, 2026.
- Acquisition: Acquired UK Biocentre Limited on March 4, 2026, for approximately $27.5 million net of cash, expanding the SMS segment's footprint in Europe.
- Margin Compression: Gross margin decreased to 45% for the quarter and 44% for the nine months, compared to 46% in the prior year periods, due to lower fixed-cost absorption in Sanger Sequencing and Automated Stores, and higher inventory reserves.
Guidance, Outlook, and Risks
- Management Commentary: Management expects to complete restructuring initiatives by the end of fiscal year 2026. The company is focusing on driving revenue growth and profitability in its core SMS and Multiomics segments following the divestiture of B Medical Systems.
- Share Repurchases: Under the 2025 Repurchase Program ($250 million authorization), the company repurchased 2.3 million shares for $50.0 million during the quarter. Approximately $200 million remains available for future repurchases.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses in the review of the cash flow statement and account reconciliations. Remediation plans are underway, including new reporting tools and reconciliation policies.
- Legal Contingency: A lawsuit filed by Edwards Vacuum LLC regarding the 2019 sale of the semiconductor cryogenics business was dismissed in July 2026 on statute of limitations grounds. The company reduced its accrual for this loss contingency by $1.8 million.
- Vendor Loan Risk: The sale of B Medical Systems included a $35.0 million secured vendor loan to the buyer. The company faces credit risk if the buyer fails to repay the loan, which matures three months post-closing.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the inputs used in the quantitative goodwill impairment test (discount rates, growth rates) for the SMS and Multiomics segments to assess the risk of future impairments.
- Internal Control Remediation: Monitor the progress of remediation for the material weaknesses in cash flow reporting and account reconciliations to ensure future financial statement reliability.
- Vendor Loan Repayment: Track the repayment status of the $35.0 million vendor loan to Thelema S.à r.l. related to the B Medical Systems divestiture.
- Segment Margins: Analyze the drivers of margin compression in the SMS segment, specifically regarding Automated Stores rework costs and inventory reserves.
- Discontinued Operations: Confirm the final accounting treatment and any remaining liabilities associated with the B Medical Systems sale and the Edwards Vacuum litigation.